ES2605228T3 - Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40 - Google Patents

Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40 Download PDF

Info

Publication number
ES2605228T3
ES2605228T3 ES10715067.4T ES10715067T ES2605228T3 ES 2605228 T3 ES2605228 T3 ES 2605228T3 ES 10715067 T ES10715067 T ES 10715067T ES 2605228 T3 ES2605228 T3 ES 2605228T3
Authority
ES
Spain
Prior art keywords
expression
antibody
sample
seq
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10715067.4T
Other languages
English (en)
Spanish (es)
Inventor
David Dornan
Bart Burington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2605228T3 publication Critical patent/ES2605228T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES10715067.4T 2009-04-18 2010-04-17 Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40 Active ES2605228T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17061509P 2009-04-18 2009-04-18
US170615P 2009-04-18
PCT/US2010/031528 WO2010121231A1 (en) 2009-04-18 2010-04-17 Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies

Publications (1)

Publication Number Publication Date
ES2605228T3 true ES2605228T3 (es) 2017-03-13

Family

ID=42358184

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10715067.4T Active ES2605228T3 (es) 2009-04-18 2010-04-17 Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40

Country Status (12)

Country Link
US (1) US9617600B2 (cg-RX-API-DMAC7.html)
EP (1) EP2419531B1 (cg-RX-API-DMAC7.html)
JP (1) JP5836929B2 (cg-RX-API-DMAC7.html)
KR (1) KR101787768B1 (cg-RX-API-DMAC7.html)
CN (1) CN102459639A (cg-RX-API-DMAC7.html)
AU (1) AU2010236168B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1011394A8 (cg-RX-API-DMAC7.html)
CA (1) CA2758523C (cg-RX-API-DMAC7.html)
ES (1) ES2605228T3 (cg-RX-API-DMAC7.html)
IL (1) IL215707A (cg-RX-API-DMAC7.html)
MX (1) MX2011010938A (cg-RX-API-DMAC7.html)
WO (1) WO2010121231A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101620642B1 (ko) 2007-11-07 2016-05-12 제넨테크, 인크. 항-cd40 항체를 사용한 치료에 대한 b-세포 림프종의 반응성 평가를 위한 방법 및 조성물
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
ES2634254T3 (es) 2011-09-12 2017-09-27 Atrys Health, SA Métodos para el pronóstico del linfoma difuso de linfocitos B grandes
KR20210073616A (ko) 2012-08-09 2021-06-18 셀진 코포레이션 면역-관련 및 염증성 질환의 치료
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
CA2888763A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
TWI745271B (zh) 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
AU2016326499A1 (en) * 2015-09-25 2018-04-12 Celgene Corporation Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP4256087A4 (en) * 2020-12-02 2024-12-04 Albert Einstein College of Medicine METHOD FOR PREDICTING PATIENT RESPONSE TO CD40-TARGETED THERAPIES
CN117092336B (zh) * 2023-06-16 2026-06-05 中国医学科学院北京协和医院 血浆n4bp1、creb1、ubap2、deaf1自身抗体标志物在弥漫大b细胞淋巴瘤预后预测中的应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
CA2402525A1 (en) 2000-03-31 2001-10-11 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
JP4679035B2 (ja) 2001-04-02 2011-04-27 ジェネンテック, インコーポレイテッド 併用療法
JP4025881B2 (ja) 2001-04-27 2007-12-26 キリンファーマ株式会社 抗cd40モノクローナル抗体
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2004071572A2 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US7711492B2 (en) 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
AU2004287879C1 (en) 2003-11-04 2011-05-26 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
PL1682177T3 (pl) 2003-11-04 2011-03-31 Novartis Vaccines & Diagnostics Inc Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP2312315A1 (en) * 2005-05-18 2011-04-20 Novartis AG Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
AU2006247067B2 (en) * 2005-05-18 2012-06-07 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
JP5027804B2 (ja) 2005-05-26 2012-09-19 シアトル ジェネティクス,インコーポレーテッド ヒト化抗cd40抗体およびその使用方法
EP2687608B1 (en) * 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
EP1943523A2 (en) * 2005-09-16 2008-07-16 Biovator Technologies AB In vitro assay for identification of allergenic proteins
DE102005052384B4 (de) * 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
MX2008007140A (es) 2005-12-09 2009-03-04 Seattle Genetics Inc Metodos para utilizar agentes de union a cd40.
US7527774B2 (en) 2005-12-22 2009-05-05 Basf Catalysts Llc Inlet metallic foam support coupled to precious metal catalyst for application on 4 stroke platforms
US20090075272A1 (en) * 2006-01-20 2009-03-19 Hollmann C Annette Method to Identify CD40-Sensitive Cells Using Gene Expression
WO2008079269A2 (en) 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
KR101620642B1 (ko) * 2007-11-07 2016-05-12 제넨테크, 인크. 항-cd40 항체를 사용한 치료에 대한 b-세포 림프종의 반응성 평가를 위한 방법 및 조성물

Also Published As

Publication number Publication date
EP2419531A1 (en) 2012-02-22
WO2010121231A1 (en) 2010-10-21
IL215707A0 (en) 2012-01-31
JP5836929B2 (ja) 2015-12-24
KR101787768B1 (ko) 2017-10-18
JP2012523838A (ja) 2012-10-11
BRPI1011394A2 (pt) 2016-03-15
KR20120013992A (ko) 2012-02-15
AU2010236168B2 (en) 2015-08-13
BRPI1011394A8 (pt) 2018-06-26
IL215707A (en) 2016-08-31
US20120123695A1 (en) 2012-05-17
US9617600B2 (en) 2017-04-11
AU2010236168A1 (en) 2011-11-10
MX2011010938A (es) 2012-01-12
CA2758523C (en) 2019-03-12
CA2758523A1 (en) 2010-10-21
CN102459639A (zh) 2012-05-16
EP2419531B1 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
Kallioniemi Biochip technologies in cancer research
ES2538504T3 (es) Marcadores en la orina para la detección del cáncer de vejiga
EP2154245B1 (en) Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
ES2653851T3 (es) Biomarcadores transcriptómicos para evaluación de riesgo individual en insuficiencia cardíaca de nueva aparición
JP4435259B2 (ja) 微量胃癌細胞の検出法
WO2002009573A2 (en) Prognostic classification of endometrial cancer
US9102706B2 (en) Newly identified colon cancer marker and diagnostic kit using the same
JP5031581B2 (ja) Aml、b−allおよびt−allの診断用マーカー
WO2006080597A1 (en) Markers for the diagnosis of lung cancer
CN108474041A (zh) 使用遗传标记的甲基化状态区分转移性-致死性前列腺癌与惰性前列腺癌
KR101182974B1 (ko) 림프종 진단 또는 예후 마커로서 Pellino 1
KR101054952B1 (ko) 간암 진단 및 환자 생존기간 예측용 마커인 uqcrh, 그를 포함하는 키트 및 상기 마커를 이용한 간암 환자 생존기간 예측
CN116949168B (zh) Cd73在帕金森病诊断中的应用
JP4317854B2 (ja) 微量胃癌細胞の検出法
KR20110097498A (ko) 전자파 노출을 진단하기 위한 마커 및 이를 포함하는 키트
EP2669384B1 (en) Method for evaluating the presence of rheumatoid arthritis and biomarker set used in the same
WO2006132983A2 (en) Differential expression of molecules associated with vascular disease risk
CN118957067B (zh) 一种胸部肿瘤诊断标志物cpd及其相关诊断产品和应用
KR101069593B1 (ko) 급성심근경색 진단용 마커
KR20110097497A (ko) 전자파 노출을 진단하기 위한 마커 및 이를 포함하는 키트
CN119193847A (zh) Gsdmd在诊断胰腺癌中的应用
CN116875673A (zh) 一种诊断心肌梗死的系统
KR101006226B1 (ko) 간암을 진단하기 위한 마커인 cxcl2, 그를 포함하는키트 및 상기 마커를 이용한 간암 예측 방법
KR20240086742A (ko) 브루셀라 캐니스균의 조기 감염 진단을 위한 숙주 바이오마커 및 이의 용도
KR20100086363A (ko) 간암을 진단 및 치료하기 위한 분자인 snx14, 그를 포함하는 키트